Search results
Author(s):
Muhammad Shahzeb Khan
,
Javed Butler
Added:
4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events…
View more
Author(s):
Thomas A Zelniker
,
Eugene Braunwald
Added:
3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the…
View more
SGLT2i in HFpEF
Author(s):
Mauro Gori
,
Emilia D’Elia
,
Edoardo Sciatti
,
et al
Added:
1 year ago
Article
SGLT2 Inhibitors in HFpEF
Author(s):
Brent Deschaine
,
Sahil Verma
,
Hussein Rayatzadeh
Added:
1 year ago
Article
Foreword
Author(s):
Andrew JS Coats
,
Giuseppe Rosano
Added:
3 years ago
Article
Eugene Braunwald
Research Area(s) / Expertise:
Job title: Distinguished Hersey Professor of Medicine, MACC
Author
Author(s):
Zachary L Cox
,
Shuktika Nandkeolyar
,
Andrew J Johnson
,
et al
Added:
1 year ago
Author(s):
Anjali Agarwalla
,
Jadry Gruen
,
Carli Peters
,
et al
Added:
2 years ago
Author(s):
Vincenzo Castiglione
,
Francesco Gentile
,
Nicolò Ghionzoli
,
et al
Added:
9 months ago
Author(s):
Sigrid L Johannesen
,
Colin M Barker
,
Melissa M Levack
Added:
2 years ago